Thoratec Announces Chief Financial Officer Transition Will Occur at End of 2006
31 August 2006 - 7:30AM
PR Newswire (US)
PLEASANTON, Calif., Aug. 30 /PRNewswire-FirstCall/ -- Thoratec
Corporation (NASDAQ:THOR), a world leader in products to treat
cardiovascular disease, said today that Cynthia Lucchese will be
stepping down from her position as senior vice president and chief
financial officer for personal reasons. Ms. Lucchese plans to
remain in her current position through the end of the year and will
assist the company in ensuring a smooth transition to a new chief
financial officer. "Cindy has greatly strengthened Thoratec's
finance organization during her tenure here and I am confident that
her team can meet our needs during this transition period," said
Gary F. Burbach, president and chief executive officer of Thoratec.
"Cindy will be missed, however we support her decision to resume
living in Indianapolis. We have initiated a search for her
replacement." "I have greatly appreciated the opportunity to work
for such an outstanding organization. Our talented, dedicated
employees, strong financial position, and exciting growth
opportunities with HeartMate(R) II made my decision a particularly
difficult one," said Ms. Lucchese. "It is certainly with regret
that changes in my personal and family situation necessitate this
decision." Thoratec Corporation is a world leader in therapies to
address advanced stage heart failure. The company's product line
includes the Thoratec(R) VAD (Ventricular Assist Device) and
HeartMate LVAS (Left Ventricular Assist System) with more than
10,000 devices implanted in patients suffering from heart failure.
Additionally, its International Technidyne Corporation (ITC)
division supplies blood testing and skin incision products.
Thoratec is headquartered in Pleasanton, California. For more
information, visit the company's web sites at
http:///www.thoratec.com or http://www.itcmed.com/ . Many of the
preceding paragraphs contain forward-looking statements within the
meaning of Section 27A of the Securities Act of 1933 and Section
21E of the Securities Exchange Act of 1934. These statements can be
identified by the words, "expects," "hopes," "believes," and other
similar words. Actual results, events or performance could differ
materially from these forward-looking statements based on a variety
of factors, many of which are beyond Thoratec's control. Therefore,
readers are cautioned not to put undue reliance on these
statements. Forward-looking statements contained in this press
release should be considered in light of those factors discussed
from time to time in Thoratec's public reports filed with the
Securities and Exchange Commission, such as those discussed under
the heading, "Risk Factors," in Thoratec's most recent annual
report on Form 10-K. These forward-looking statements speak only as
of the date hereof. Thoratec undertakes no obligation to publicly
release the results of any revisions to these forward-looking
statements that may be made to reflect events or circumstances
after the date hereof, or to reflect the occurrence of
unanticipated events. DATASOURCE: Thoratec Corporation CONTACT:
Cynthia Lucchese, Senior Vice President, Chief Financial Officer of
Thoratec Corporation, +1-925-847-8600; or Neal Rosen of Kalt Rosen
& Co., +1-415-397-2686, for Thoratec Corporation Web site:
http://www.thoratec.com/ http://www.itcmed.com/
Copyright
Synthorx (NASDAQ:THOR)
Historical Stock Chart
From Sep 2024 to Oct 2024
Synthorx (NASDAQ:THOR)
Historical Stock Chart
From Oct 2023 to Oct 2024
Real-Time news about Synthorx Inc (NASDAQ): 0 recent articles
More Thoratec (MM) News Articles